# Article information:

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial - The Lancet Respiratory Medicine
[https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2821%2900494-X/fulltext)

# Article summary:

1. The LIVE-AIR trial investigated the efficacy and safety of lenzilumab, a GM-CSF neutralising monoclonal antibody, in treating COVID-19 beyond available treatments.

2. The primary endpoint was survival without invasive mechanical ventilation to day 28 in the modified intention-to-treat population (mITT).

3. Lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with COVID-19, with a safety profile similar to that of placebo.

# Article rating:

Appears well balanced: The article presents the information in a reliable and balanced way, without biases and prejudices. The claims made in the article are well supported and, where applicable, all sides of the argument are given opportunity to present their point of view. The article appears trustworthy and reliable.

# Article analysis:

The article is generally reliable and trustworthy as it provides detailed information on the LIVE-AIR trial which investigated the efficacy and safety of lenzilumab, a GM-CSF neutralising monoclonal antibody, in treating COVID-19 beyond available treatments. The primary endpoint was survival without invasive mechanical ventilation to day 28 in the modified intention-to-treat population (mITT). The article also provides detailed information on the study design, patient demographics, baseline characteristics, treatment regimens used and results obtained from the trial. Furthermore, it also mentions potential adverse events associated with lenzilumab use and their severity based on CTCAE criteria.

The article does not appear to be biased or one sided as it presents both sides of the argument equally by providing detailed information on both lenzilumab use and its potential risks. It also mentions that further research is needed to understand the added value of lenzilumab beyond other immunomodulators used to treat COVID-19 alongside steroids. Additionally, there are no promotional content or partiality present in this article as it focuses solely on presenting scientific evidence from the trial conducted.

In conclusion, this article appears to be reliable and trustworthy as it provides detailed information on the LIVE-AIR trial which investigated lenzilumab use for treating COVID-19 pneumonia and its results along with potential risks associated with its use.

# Topics for further research:

* Lenzilumab efficacy in COVID-19
* Lenzilumab safety in COVID-19
* LIVE-AIR trial design
* LIVE-AIR trial results
* Immunomodulators for COVID-19
* Adverse events associated with lenzilumab

# Report location:

<https://www.fullpicture.app/item/fdcdfc53bed31005f6d2cdd2f23e5813>